KRYS in the 13F filings
Krystal Biotech Inc · CUSIP 501147102
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 20
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 5 listed it in both
- Shares listed
- 6,879,617
- combined, among listed positions
- Reported value
- $2.6bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 12 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +275,318.
Managers listing KRYS in Q2 2026
20 of 20 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 687,400 shares now+202,326
- Invesco Ltdexisting position · 324,755 shares now+73,382
- Renaissance Technologies LLCexisting position · 59,680 shares now+50,080
- Fidelity (FMR LLC)existing position · 4,418,197 shares now+44,210
- Wellington Management Group LLPexisting position · 36,936 shares now+26,709
Reductions
- Capital World Investorsexisting position · 777,843 shares now-46,877
- Janus Henderson Group Ltdexisting position · 256,665 shares now-9,994
- Susquehanna International Group LLPexisting position · 1,899 shares now-7,143
- Freestone Grove Partners LPexisting position · 920 shares now-2,002
- Walleye Capital LLCexisting position · 12 shares now-342
New positions and exits
New (3)
Exited (7)
- Marshall Wace LLPwas $18m
- Tudor Investment Corpwas $3.7m
- Millennium Management LLCwas $1.1m
- Hudson Bay Capital Management LPwas $336k
- Squarepoint Ops LLCwas $294k
- Farallon Capital Management LLCwas $258k
- D. E. Shaw & Co.was $257k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2018 | 1 | $260k | n.a. | n.a. |
| Q1 2019 | 1 | $581k | n.a. | n.a. |
| Q2 2019 | 1 | $2.5m | n.a. | n.a. |
| Q3 2019 | 1 | $2.4m | n.a. | n.a. |
| Q4 2019 | 1 | $1.3m | n.a. | n.a. |
| Q1 2020 | 2 | $15m | n.a. | n.a. |
| Q2 2020 | 4 | $45m | n.a. | n.a. |
| Q3 2020 | 4 | $52m | n.a. | n.a. |
| Q4 2020 | 3 | $66m | n.a. | n.a. |
| Q1 2021 | 3 | $67m | n.a. | n.a. |
| Q2 2021 | 2 | $28m | n.a. | n.a. |
| Q3 2021 | 2 | $31m | n.a. | n.a. |
| Q4 2021 | 2 | $135m | n.a. | n.a. |
| Q1 2022 | 1 | $114m | n.a. | n.a. |
| Q2 2022 | 2 | $107m | n.a. | n.a. |
| Q3 2022 | 3 | $97m | n.a. | n.a. |
| Q4 2022 | 3 | $59m | n.a. | n.a. |
| Q1 2023 | 3 | $59m | n.a. | n.a. |
| Q2 2023 | 3 | $82m | n.a. | n.a. |
| Q3 2023 | 5 | $143m | n.a. | n.a. |
| Q4 2023 | 5 | $109m | 3 | 1 |
| Q1 2024 | 8 | $853m | 5 | 2 |
| Q2 2024 | 6 | $1.0bn | 5 | 0 |
| Q3 2024 | 5 | $976m | 3 | 1 |
| Q4 2024 | 5 | $850m | 4 | 0 |
| Q1 2025 | 5 | $993m | 4 | 0 |
| Q2 2025 | 4 | $746m | 1 | 2 |
| Q3 2025 | 5 | $938m | 2 | 1 |
| Q4 2025 | 7 | $1.4bn | 13 | 11 |
| Q1 2026 | 6 | $1.5bn | 15 | 11 |
| Q2 2026 | 6 | $2.4bn | 12 | 14 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
KRYS and GILD →KRYS and AMGN →KRYS and ARGX →Choose a stock to compare with KRYS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own KRYS, latest filings →Back to the 13F Explorer →